Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.

@article{Tunki2019ModulatingTS,
  title={Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.},
  author={Lakshmi Tunki and Hitesh Kulhari and Lakshma Nayak Vadithe and Madhusudana Kuncha and Suresh Kumar Bhargava and Deep Pooja and Ramakrishna Sistla},
  journal={European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences},
  year={2019},
  pages={
          104978
        }
}
  • Lakshmi Tunki, H. Kulhari, R. Sistla
  • Published 1 September 2019
  • Biology, Chemistry
  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma
TLDR
An overview of hot topics in tumor nanoscience and the latest status of treatments for HCC is provided and the current research status of nanoparticle drug delivery systems for treatment of HCC with sorafenib is introduced.
Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer
TLDR
The localized delivery of SF-loaded nanoparticles resulted in improved anti-tumor activity as compared to SF alone, and displays great potential as a novel treatment approach against certain lung cancers.
Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances
TLDR
In this review, the effect of utilizing lipidic nanoparticles is being discussed as well as the different tumor uptake enhancement techniques used.
Investigation of sorafenib tosylate loaded liposomal dry powder inhaler for the treatment of non-small cell lung cancer
TLDR
ST-LDPI was obtained by spray drying the ST loaded liposomes, evaluated for physicochemical properties and in vitro lung deposition by Andersen Cascade Impactor and showed low density and good flowability, which could be a targeted delivery of ST to the NSCLC treatment.
Size-shrinkable and protein kinase Cα-recognizable nanoparticles for deep tumor penetration and cellular internalization.
Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
TLDR
A polyamidoamine-aptamer-coated hollow mesoporous silica nanoparticle for the co-delivery of sorafenib and CRISPR/Cas9 provides a versatile delivery approach for efficient co-loading of gene-drug combinations, allowing for precise gene editing and synergistic inhibition of tumor growth without apparent side effects on normal tissues.
N-acetyl-D-glucosamine-conjugated PAMAM Dendrimers as Dual Receptor-Targeting Nanocarriers for Anticancer Drug Delivery.
  • Deep Pooja, T. Srinivasa Reddy, R. Sistla
  • Biology, Chemistry
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
  • 2020
...
1
2
...

References

SHOWING 1-10 OF 39 REFERENCES
Preparation, pharmacokinetics, tissue distribution and antitumor effect of sorafenib-incorporating nanoparticles in vivo.
TLDR
The results, provided they can be extended to humans, suggest that sorafenib nanoparticles may specifically target hepatocellular carcinoma.
Sorafenib-loaded polymeric micelles as passive targeting therapeutic agents for hepatocellular carcinoma therapy.
TLDR
SF micelles might be a potential drug delivery system, which could enhance the therapeutic effects of sorafenib, and in vivo imaging results showed PEG-poly (ε-caprolactone) micells could elevate the sorafanib concentration in tumor tissues.
Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
TLDR
The efficient delivery of VEGF siRNAs delivered by L4-LCP NPs that resulted in significant tumor regression indicates that phenyl galactoside could be a promising HCC-targeting ligand for therapeutic siRNA delivery to treat liver cancer.
Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma
TLDR
NP-SFB-Ab is a promising new method for achieving targeted therapy of HCC and significantly inhibited the growth of HepG2 xenograft tumors in nude mice without producing obvious side effects.
Improving Efficacy, Oral Bioavailability, and Delivery of Paclitaxel Using Protein-Grafted Solid Lipid Nanoparticles.
TLDR
WGA-conjugated, PTX-loaded solid lipid nanoparticles (LPSN) exhibited enhanced anticancer activity against A549 lung cancer cells after internalization through lectin receptors than free PTX, which could be due to cumulative bioadhesive property of the nanocarrier system and the targeting ligand WGA.
Nanoparticles of a polyaspartamide‐based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation
Nanomedicines for targeted delivery of etoposide to non-small cell lung cancer using transferrin functionalized nanoparticles
TLDR
The promising results of this study suggest that targeting of nanomedicines to Tf-receptors, those that are over expressed in non-small cell lung cancer could increase the therapeutic efficacy of lung cancer therapy.
Preparation and passive target of 5-fluorouracil solid lipid nanoparticles
TLDR
The results indicated that 5-FU-SLNs were promising passive targeting therapeutic agents for curing primary lung carcinoma and could improve therapeutic efficacy and reduce side-effects.
Galactosylated Liposomes for Targeted Co-Delivery of Doxorubicin/Vimentin siRNA to Hepatocellular Carcinoma
TLDR
Results suggest that Gal-DOX-siRNA-L could effectively target tumor cells, enhance transfection efficacy and subsequently achieve the co-delivery of DOX and siRNA, demonstrating great potential for synergistic anti-tumor therapy.
...
1
2
3
4
...